Cyclerion Therapeutics (CYCN) Price to Sales (2019 - 2025)

Cyclerion Therapeutics has reported Price to Sales for 6 years, with the latest figure at 9.71 in Q3 2025.

• On a quarterly basis, Price to Sales fell 71.25% year-over-year to 9.71 in Q3 2025; TTM through Sep 2025 was 2.98, a 91.19% decrease from a year earlier, with the FY2024 full-year figure at 4.1, changed N/A from the prior year.
• Price to Sales was 9.71 for Q3 2025 at Cyclerion Therapeutics, down from 96.25 in the prior quarter.
• The five-year high for Price to Sales was 1535.85 in Q1 2021, with the low at 4.54 in Q4 2024.
• Average Price to Sales over 4 years is 226.27, with a median of 77.98 recorded in 2022.
• The sharpest annual moves came in 2021 and 2022: Price to Sales soared 2124551.4% in 2021, then plunged 95.58% in 2022.
• Over 4 years, Price to Sales stood at 140.09 in 2021, then plunged by 44.33% to 77.98 in 2022, then plunged by 94.18% to 4.54 in 2024, then surged by 113.98% to 9.71 in 2025.
• The last three Price to Sales figures came in at 9.71 (Q3 2025), 96.25 (Q2 2025), and 94.47 (Q1 2025), per Business Quant data.